Related Experiment Video
Updated: Oct 14, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis
Bennett G Childs1, Cheng Zhang2, Fahad Shuja3
1Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester MN, United States.
Abstract:
Senescent cells (SNCs) degenerate the fibrous cap that normally prevents atherogenic plaque rupture, a leading cause of myocardial infarction and stroke. Here we explored the underlying mechanism using pharmacological or transgenic approaches to clear SNCs in the Ldlr -/- mouse model of atherosclerosis. SNC clearance reinforced fully deteriorated fibrous caps in highly advanced lesions, as evidenced by restored vascular smooth muscle cell (VSMC) numbers, elastin content, and overall cap thickness. We found that SNCs inhibit VSMC promigratory phenotype switching in the first interfiber space of the arterial wall directly beneath atherosclerotic plaque, thereby limiting lesion entry of medial VSMCs for fibrous cap assembly or reinforcement. SNCs do so by antagonizing IGF-1 through the secretion of insulin-like growth factor-binding protein 3 (Igfbp3). These data indicate that the intermittent use of senolytic agents or IGFBP-3 inhibition in combination with lipid lowering drugs may provide therapeutic benefit in atherosclerosis.
Insights
Clearing senescent cells (SNCs) strengthens atherosclerotic plaque fibrous caps by restoring vascular smooth muscle cells. This suggests senolytic agents may treat atherosclerosis by targeting IGFBP-3.
Area of Science:
- Cardiovascular Research
- Cellular Aging
- Atherosclerosis Pathogenesis
Background:
- Senescent cells (SNCs) contribute to atherosclerosis by weakening fibrous caps, increasing risks of myocardial infarction and stroke.
- Understanding the mechanisms by which SNCs impact plaque stability is crucial for developing new therapies.
Purpose of the Study:
- To investigate how senescent cells influence fibrous cap integrity in atherosclerosis.
- To explore the potential of senescent cell clearance as a therapeutic strategy for atherosclerosis.
Main Methods:
- Utilized the Ldlr-/- mouse model of atherosclerosis.
- Employed pharmacological and transgenic methods to clear senescent cells.
- Assessed fibrous cap composition, including vascular smooth muscle cell (VSMC) numbers, elastin content, and cap thickness.
Main Results:
- Senescent cell clearance significantly reinforced deteriorated fibrous caps in advanced atherosclerotic lesions.
- Restored VSMC numbers, elastin content, and cap thickness were observed after SNC clearance.
- Identified that SNCs inhibit VSMC migration by secreting insulin-like growth factor-binding protein 3 (Igfbp3), which antagonizes IGF-1.
Conclusions:
- Senescent cells impair fibrous cap integrity by inhibiting VSMC recruitment via the Igfbp3/IGF-1 pathway.
- Intermittent senolytic therapy or Igfbp3 inhibition, combined with lipid-lowering drugs, shows therapeutic potential for atherosclerosis.
More Related Videos
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
Related Concept Videos
Atherosclerosis I: Introduction
Inflammation
The Effect of Aging on Tissues
Mesenchymal Stem Cells
Coronary Artery Disease II: Pathophysiology